Compare FTAI Aviation Ltd (FTAI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? FTAI Aviation Ltd trades at $169.36 (market cap $17.57B), while State Street SPDR S&P Biotech ETF trades at $154.12 (market cap $10.11B). The key difference: FTAI Aviation Ltd is the larger of the two by market cap, and FTAI Aviation Ltd pays a 1.17% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold FTAI Aviation Ltd for 22 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| FTAI | XBI | |
|---|---|---|
Market Cap | $17.57B | $10.11B |
Volume | 1,905,014 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $310.04 | $169.55 |
52-Week Low | $152.80 | $104.99 |
Typical Hold Time | 22 Days | 37 Days |
Enterprise Value | $20.69B | — |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation Ltd. (FTAI) trades at $169.13, down 3.26% over 24 hours, with a bearish technical signal from moving averages. Recent financials show strong revenue growth to $2.51B in 2025 and a net income margin of 15.94%, but earnings have missed expectations for three consecutive quarters. The company announced a $500 million share repurchase program and a strategic aircraft acquisition, signaling management confidence. Valuation ratios are elevated, with a P/E of 37.35 and P/B of 43.49, reflecting high growth expectations.
The outlook for FTAI is mixed; analyst consensus is unanimously bullish with a $321.25 price target, but near-term risks include earnings misses and negative operating cash flow. Long-term growth drivers include expansion in aerospace products and power segments, though execution risks and market volatility could pressure the stock. Investors should weigh strong institutional support against fundamental headwinds.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
